This page uses content from Wikipedia and is licensed under CC BY-SA.
List of miscellaneous designer cannabinoids
Since the first synthetic cannabinoids were discovered in recreational drug products in 2008, new synthetic cannabinoids with no precedent in the scientific literature continue to be identified. These synthetic cannabinoids appear to be rationally designed by clandestine medicinal chemists. These unprecedented synthetic cannabinoids often feature alphanumeric code names intended to mimic the style of chemical nomenclature used by academic laboratories and pharmaceutical companies, and there is generally little, if any, information available regarding their pharmacology and toxicology at the time of first discovery.
AB-001 — one of the earliest adamantane derivatives discovered as a designer cannabinoid. AB-001 was unknown in the scientific literature at the time of its discovery, and has since been characterized as a CB1 and CB2 agonist with weak cannabimimetic activity in rats.
APICA — also known as 2NE1 and SDB-001, APICA is the carboxamide analogue of AB-001 and was similarly unknown in the scientific literature at the time of its discovery. Like AB-001, APICA is a CB1 and CB2 agonist possessing moderate cannabimimetic potency in rats.
^Banister, S. D.; Moir, M.; Stuart, J.; Kevin, R. C.; Wood, K. E.; Longworth, M.; Wilkinson, S. M.; Beinat, C.; Buchanan, A. S.; Glass, M.; Connor, M.; McGregor, I. S.; Kassiou, M. (Sep 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA". ACS Chem Neurosci. 6 (9): 1546–59. doi:10.1021/acschemneuro.5b00112. PMID26134475.
^ abcBanister, SD; Stuart, J; Kevin, RC; Edington, A; Longworth, M; Wilkinson, SM; Beinat, C; Buchanan, AS; Hibbs, DE; Glass, M; Connor, M; McGregor, IS; Kassiou, M (2015). "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chem Neurosci. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID25921407.
^Uchiyama, N.; Kawamura, M.; Kikura-Hanajiri, R.; Goda, Y. (2012). "URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products". Forensic Science International. 227 (1–3): 21–32. doi:10.1016/j.forsciint.2012.08.047. PMID23063179.
^Antoni R. Blaazer; et al. (October 2011). "Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure–activity relationships, physicochemical properties and biological activity". European Journal of Medicinal Chemistry. 46 (10): 5086–5098. doi:10.1016/j.ejmech.2011.08.021. PMID21885167.
^Wilkinson, S. M.; Banister, S. D.; Kassiou, M. (2015). "Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids". Australian Journal of Chemistry. 68: 4. doi:10.1071/CH14198.